KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Total Liabilities (2016 - 2025)

Arbutus Biopharma's Total Liabilities history spans 16 years, with the latest figure at $20.3 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 39.46% year-over-year to $20.3 million; the TTM value through Sep 2025 reached $20.3 million, down 39.46%, while the annual FY2024 figure was $34.3 million, 10.53% down from the prior year.
  • Total Liabilities for Q3 2025 was $20.3 million at Arbutus Biopharma, roughly flat from $20.3 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $62.7 million in Q2 2022 and bottomed at -$165.8 million in Q1 2022.
  • The 5-year median for Total Liabilities is $35.7 million (2024), against an average of $28.3 million.
  • The largest annual shift saw Total Liabilities crashed 616.8% in 2022 before it surged 128.53% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $35.0 million in 2021, then surged by 67.11% to $58.6 million in 2022, then crashed by 34.46% to $38.4 million in 2023, then fell by 10.53% to $34.3 million in 2024, then crashed by 40.85% to $20.3 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Total Liabilities are $20.3 million (Q3 2025), $20.3 million (Q2 2025), and $37.9 million (Q1 2025).